Are you Dr. Klein?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 44 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
500 Harvard St Se
Ump Laboratory Medicine & Pathology
Minneapolis, MN 55455Phone+1 612-273-3000Fax+1 608-265-3301
Summary
- Dr. Molly Klein, MD is a board certified pathologist in Minneapolis, Minnesota. She is currently licensed to practice medicine in Minnesota, Missouri, and Wisconsin. She is affiliated with M Health Fairview University of Minnesota Medical Center.
Education & Training
UPMC Medical Education (Presbyterian Shadyside Hospital) AFellowship, Selective Pathology, 2010 - 2011
Washington University/B-JH/SLCH ConsortiumFellowship, Selective Pathology, 2009 - 2010- Washington University/B-JH/SLCH ConsortiumResidency, Pathology-Anatomic and Clinical, 2006 - 2009
- Washington University/B-JH/SLCH ConsortiumResidency, Obstetrics and Gynecology, 1994 - 1998
- Washington University in St. Louis School of MedicineClass of 1994
Certifications & Licensure
MN State Medical License 2013 - 2025
MO State Medical License Active through 2013
WI State Medical License Active through 2013- American Board of Pathology Pathology - Anatomic
Publications & Presentations
PubMed
- 17 citationsPredicted sensitivity to endocrine therapy for stage II-III hormone receptor-positive and HER2-negative (HR+/HER2−) breast cancer before chemo-endocrine therapyLili Du, Christina Yau, Lamorna Brown-Swigart, Rebekah Gould, Gregor Krings
Annals of Oncology. 2021-02-19 - 79 citationsSingle cell sequencing reveals heterogeneity within ovarian cancer epithelium and cancer associated stromal cellsBoris Winterhoff, Makayla Maile, Amit Kumar Mitra, Attila Sebe, Martina Bazzaro
Gynecologic Oncology. 2017-03-01 - 17 citationsTumor-Stroma Proportion as a Predictive Biomarker of Resistance to Platinum-Based Chemotherapy in Patients With Ovarian Cancer.Emil Lou, Rachel Isaksson Vogel, Spencer Hoostal, Molly Klein, Michael A. Linden
JAMA Oncology. 2019-06-01
